ABSTRACT
Multiple Sclerosis (MS) is an infl ammatory demyelinating disease of Central Nervous System (CNS) (Poser and Brinar, 2004). Dysregulation of Th1, Th2, and Th17 cytokines is a key concept for the pathogenesis of MS (McFarland and Martin, 2007). It also shows axonal transection as a consequence of demyelination (Trapp et al., 1998), suggesting neurodegenerative component in its pathology. Typical presenting symptoms of MS include sensory disturbances, unilateral Optic Neuritis (ON), diplopia (internuclear ophthalmoplegia), Lhermitte’s sign (trunk and limb paresthesi as evoked by neck fl exion), limb weakness, clumsiness, gait ataxia, and neurogenic bladder and bowel symptoms (Noseworthy et al., 2000). Currently, there is no specifi c and defi nite test to diagnose MS, and thus MS is a diagnosis with constellation of clinical features and test results, as well as with exclusion of other autoimmune CNS demyelinating diseases, including acute disseminating encephalomyelitis (ADEM), transverse myelitis (idiopathic or secondary to other autoimmune disease such as systemic lupus erythematosus and Sjogren’s disease), neuromyelitis optica (NMO), and neurosarcoidosis.
